![Joseph Pearlberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Pearlberg
Direktor/Vorstandsmitglied bei
Neomorph, Inc.
Vermögen: 635 531 $ am 30.06.2026
Profil
Joseph Pearlberg is currently Director at Neomorph, Inc., Associate at The Broad Institute, Inc., and Vice President at Deerfield Management Co. LP (Private Equity) since 2017.
Former roles include Medical Director at Sanofi, Independent Director at Nuvalent, Inc. from 2021 to 2026, and Vice President-Clinical Development at Infinity Pharmaceuticals, Inc. from 2016 to 2017.
Education includes a doctorate from Harvard University conferred in 1994, an undergraduate degree from the University of Pennsylvania conferred in 1985, and a doctorate from The University of California, San Francisco conferred in 1999.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUVALENT, INC. CLASS A 0,01 % | 18.06.2025 | 5.146 ( 0,01 % ) | 635 531 $ | 30.06.2026 |
Aktive Positionen von Joseph Pearlberg
| Unternehmen | Position | Beginn |
|---|---|---|
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Corporate Officer/Principal | - |
Neomorph, Inc.
 Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Direktor/Vorstandsmitglied | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Private Equity Investor | 01.07.2017 |
Ehemalige bekannte Positionen von Joseph Pearlberg
| Unternehmen | Position | Ende |
|---|---|---|
| NUVALENT, INC. | Direktor/Vorstandsmitglied | 16.06.2026 |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2017 |
| SANOFI | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Joseph Pearlberg
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Health Technology |
